Skip to main content

Teva taps Eric Hughes as chief medical officer

Hughes brings nearly 20 years of leadership roles, with a proven track record in a variety of R&D functions, to global pharmaceutical companies, Teva said.
eric a hughes headshot
Eric Hughes

Eric Hughes is joining Teva as executive vice president of global R&D and chief medical officer.

Hughes will begin his employment on Aug. 1 based out of Teva's U.S. headquarters in Parsippany, N.J.

“I am thrilled to join Teva's executive management team and lead its unique, integrated global R&D organization," Hughes said. "Building on Teva's strong heritage of value creation, we have a tremendous opportunity to bring meaningful specialty, biologics and generics medicines to patients worldwide.”

Hughes joins Teva with nearly 20 years of experience in all phases of drug development at leading global pharmaceutical companies, most recently as senior vice president of clinical development and translational medicine at Vertex Pharmaceuticals, and prior to that as head of the immunology, hepatology and dermatology global development unit at Novartis.

"Eric brings nearly 20 years of leadership roles with a proven track record in a variety of R&D functions for global pharmaceutical companies, and has a successful record of accomplishment fostering productive collaborations with key opinion leaders and patient advocacy groups,” said Kåre Schultz, Teva's president and CEO. "As an accomplished scientist with specialty training in infectious diseases and immunology, combined with his track record of leading clinical development activities and talent across multiple therapeutic areas around the globe, I believe Eric has the experience and expertise to lead our global R&D function and execute on the company-wide vision for innovation and growth going forward."

Hughes earned his master's degree and doctorate at Yale School of Medicine. He completed his medical residency with the Department of Internal Medicine at Yale New Haven Hospital/Yale University School of Medicine and a fellowship in infectious diseases at the Yale University School of Medicine. He is a prolific and widely published scientist, co-authoring more than 30 articles in peer-reviewed scientific journals and has a deep passion for helping patients.

"On behalf of the board of directors and our leadership team, I would also like to take this opportunity to thank Dr. Hafrun Fridriksdottir for over 25 years of service to Teva and its legacy companies," Schultz said. "Hafrun has been an integral part of my executive management team, and I wish her good luck as she embarks on her next adventure."

This ad will auto-close in 10 seconds